{"id":511310,"date":"2021-07-09T07:36:03","date_gmt":"2021-07-09T11:36:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/"},"modified":"2021-07-09T07:36:03","modified_gmt":"2021-07-09T11:36:03","slug":"salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/","title":{"rendered":"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference"},"content":{"rendered":"
\n

HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc.<\/a> (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer, will present virtually at\u00a0the 2021 Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 3 p.m., ET. The presentation can be accessed via the conference\u2019s virtual platform by registered conference attendees.<\/p>\n

Mr. Arthur will provide an overview of Salarius\u2019 business and highlight recent corporate and clinical achievements, as well as anticipated milestones in the clinical programs for seclidemstat, a reversible LSD1 inhibitor. Salarius is currently advancing a Phase 1\/2 dose-expansion study evaluating seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide (TC) as a potential second- and third-line therapy for Ewing sarcoma, and as a single-agent treatment for other FET-rearranged sarcomas. In addition, Salarius recently announced the initiation of a Phase 1\/2 clinical trial to study seclidemstat as a potential treatment for hematologic cancers.<\/p>\n

Details of the presentation are as follows:\u00a0<\/p>\n\n\n\n\n\n
\n Event:<\/strong>\n <\/td>\n2021 Ladenburg Thalmann Healthcare Conference<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nTuesday, July 13, 2021<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n3:00 p.m. ET to 3:25 p.m. ET<\/td>\n<\/tr>\n
\n Webcast: <\/strong>\n <\/td>\n\n https:\/\/wsw.meetmax.com\/webcast\/ladenburg7\/register.aspx<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

Members of the Salarius management team will be available to participate in one-on-one virtual meetings with registered investors and pharmaceutical companies.<\/p>\n

Following the conclusion of the event, a recording of Mr. Arthur\u2019s presentation will be available under \u201cEvents & Presentations\u201d in the Investors section of the Company\u2019s website at\u00a0http:\/\/www.salariuspharma.com<\/a> .<\/p>\n

\n About Salarius Pharmaceuticals<\/strong>\n <\/p>\n

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1\/2 clinical trial for relapsed\/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1\/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com<\/a> or follow Salarius on Twitter and LinkedIn.<\/p>\n

\n Contact<\/strong>
\n
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA
(212) 375-2664
mmcenroe@tiberend.com<\/a><\/p>\n

Johanna Bennett (media relations)
(212)\u00a0375-2686\u00a0
jbennett@tiberend.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer, will present virtually at\u00a0the 2021 Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 3 p.m., ET. The presentation can be accessed via the conference\u2019s virtual platform by registered conference attendees. Mr. Arthur will provide an overview of Salarius\u2019 business and highlight recent corporate and clinical achievements, as well as anticipated milestones in the clinical programs for seclidemstat, a reversible LSD1 inhibitor. Salarius is currently advancing a Phase 1\/2 dose-expansion study evaluating seclidemstat in combination with the chemotherapy agents topotecan and … <\/p>\n

Continue reading “Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511310","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSalarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer, will present virtually at\u00a0the 2021 Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 3 p.m., ET. The presentation can be accessed via the conference\u2019s virtual platform by registered conference attendees. Mr. Arthur will provide an overview of Salarius\u2019 business and highlight recent corporate and clinical achievements, as well as anticipated milestones in the clinical programs for seclidemstat, a reversible LSD1 inhibitor. Salarius is currently advancing a Phase 1\/2 dose-expansion study evaluating seclidemstat in combination with the chemotherapy agents topotecan and … Continue reading "Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-09T11:36:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference\",\"datePublished\":\"2021-07-09T11:36:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/\"},\"wordCount\":461,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/\",\"name\":\"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=\",\"datePublished\":\"2021-07-09T11:36:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference - Market Newsdesk","og_description":"HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer, will present virtually at\u00a0the 2021 Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 3 p.m., ET. The presentation can be accessed via the conference\u2019s virtual platform by registered conference attendees. Mr. Arthur will provide an overview of Salarius\u2019 business and highlight recent corporate and clinical achievements, as well as anticipated milestones in the clinical programs for seclidemstat, a reversible LSD1 inhibitor. Salarius is currently advancing a Phase 1\/2 dose-expansion study evaluating seclidemstat in combination with the chemotherapy agents topotecan and … Continue reading \"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-09T11:36:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference","datePublished":"2021-07-09T11:36:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/"},"wordCount":461,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/","name":"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=","datePublished":"2021-07-09T11:36:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzcwOCM0Mjg5NTUzIzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-present-at-the-virtual-ladenburg-thalmann-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511310"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511310\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}